A Retrospective Validation Study To Identify Chart-Based Clinical Diagnosis Of Wild-Type Transthyretin Amyloid Cardiomyopathy (Attrwt-CM) And Non-Amyloid Heart Failure Among Patients With Heart Failure (HF).

CompletedOBSERVATIONAL

Enrollment

558

Participants

Timeline

Start Date

September 1, 2023

Primary Completion Date

November 14, 2023

Study Completion Date

November 14, 2023

Conditions

ATTR-CM

Interventions

OTHER

Machine learning algorithm

Software to calculate the predicted probability of ATTRwt-CM for these heart failure patients based on the presence and absence of certain features

Trial Locations (1)

Pfizer, New York